Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,918 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
Stone GW, Mehran R, Goldstein P, Witzenbichler B, Van't Hof A, Guagliumi G, Hamm CW, Généreux P, Clemmensen P, Pocock SJ, Gersh BJ, Bernstein D, Deliargyris EN, Steg PG. Stone GW, et al. Among authors: bernstein d. J Am Coll Cardiol. 2015 Jan 6;65(1):27-38. doi: 10.1016/j.jacc.2014.10.029. J Am Coll Cardiol. 2015. PMID: 25572507 Free article.
Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
Geisler T, Müller K, Karathanos A, Bocksch W, Gawaz M, Deliargyris E, Bernstein D, Lincoff AM, Mehran R, Dangas G, Stone GW. Geisler T, et al. Among authors: bernstein d. EuroIntervention. 2014 May;10(1):97-104. doi: 10.4244/EIJV10I1A16. EuroIntervention. 2014. PMID: 24048204 Free article.
Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial.
Zeymer U, van 't Hof A, Adgey J, Nibbe L, Clemmensen P, Cavallini C, ten Berg J, Coste P, Huber K, Deliargyris EN, Day J, Bernstein D, Goldstein P, Hamm C, Steg PG. Zeymer U, et al. Among authors: bernstein d. Eur Heart J. 2014 Sep 21;35(36):2460-7. doi: 10.1093/eurheartj/ehu214. Epub 2014 May 21. Eur Heart J. 2014. PMID: 24849104 Free PMC article. Clinical Trial.
Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography).
Clemmensen P, Wiberg S, Van't Hof A, Deliargyris EN, Coste P, Ten Berg J, Cavallini C, Hamon M, Dudek D, Zeymer U, Tabone X, Kristensen SD, Bernstein D, Anthopoulos P, Prats J, Steg PG. Clemmensen P, et al. Among authors: bernstein d. JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):214-220. doi: 10.1016/j.jcin.2014.11.002. JACC Cardiovasc Interv. 2015. PMID: 25616927 Free article. Clinical Trial.
Impact of arterial access site on outcomes after primary percutaneous coronary intervention: prespecified subgroup analysis from the EUROMAX trial.
Hamon M, Coste P, Van't Hof A, Ten Berg J, Clemmensen P, Tabone X, Benamer H, Kristensen SD, Cavallini C, Marzocchi A, Hamm C, Kanic V, Bernstein D, Anthopoulos P, Deliargyris EN, Steg PG. Hamon M, et al. Among authors: bernstein d. Circ Cardiovasc Interv. 2015 Jun;8(6):e002049. doi: 10.1161/CIRCINTERVENTIONS.114.002049. Circ Cardiovasc Interv. 2015. PMID: 26056249 Clinical Trial.
ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMAX ST-segment resolution substudy.
Van't Hof A, Giannini F, Ten Berg J, Tolsma R, Clemmensen P, Bernstein D, Coste P, Goldstein P, Zeymer U, Hamm C, Deliargyris E, Steg PG. Van't Hof A, et al. Among authors: bernstein d. Eur Heart J Acute Cardiovasc Care. 2017 Aug;6(5):404-411. doi: 10.1177/2048872615598633. Epub 2015 Aug 6. Eur Heart J Acute Cardiovasc Care. 2017. PMID: 26250825 Clinical Trial.
Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial.
Dangas GD, Lefèvre T, Kupatt C, Tchetche D, Schäfer U, Dumonteil N, Webb JG, Colombo A, Windecker S, Ten Berg JM, Hildick-Smith D, Mehran R, Boekstegers P, Linke A, Tron C, Van Belle E, Asgar AW, Fach A, Jeger R, Sardella G, Hink HU, Husser O, Grube E, Deliargyris EN, Lechthaler I, Bernstein D, Wijngaard P, Anthopoulos P, Hengstenberg C; BRAVO-3 Investigators. Dangas GD, et al. Among authors: bernstein d. J Am Coll Cardiol. 2015 Dec 29;66(25):2860-2868. doi: 10.1016/j.jacc.2015.10.003. Epub 2015 Oct 15. J Am Coll Cardiol. 2015. PMID: 26477635 Free article. Clinical Trial.
Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trial.
Kilic S, Van't Hof AW, Ten Berg J, Lopez AA, Zeymer U, Hamon M, Soulat L, Bernstein D, Deliargyris EN, Steg PG. Kilic S, et al. Among authors: bernstein d. Int J Cardiol. 2016 May 15;211:119-23. doi: 10.1016/j.ijcard.2016.02.131. Epub 2016 Mar 3. Int J Cardiol. 2016. PMID: 26995053 Clinical Trial.
Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials.
Dangas GD, Schoos MM, Steg PG, Mehran R, Clemmensen P, van 't Hof A, Prats J, Bernstein D, Deliargyris EN, Stone GW. Dangas GD, et al. Among authors: bernstein d. Circ Cardiovasc Interv. 2016 May;9(5):e003272. doi: 10.1161/CIRCINTERVENTIONS.115.003272. Circ Cardiovasc Interv. 2016. PMID: 27165710 Clinical Trial.
1,918 results